REUN Reunion Neuroscience Inc

Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will participate in the Cantor Neurology & Psychiatry Conference taking place on October 6-7, 2022 at the Ritz Carlton, San Francisco.

The Reunion management team will participate in the panel presentation, “Tripping Our Way to a New Treatment Paradigm for Psychiatric Disorders: Intermittent Therapy vs Chronic Treatment,” on Thursday, October 6 at 12:10-1:10 PM Pacific Time / 3:10-4:10 PM Eastern Time in Track 1.

Management will also take part in one-on-one meetings over the duration of the conference. Institutional investors interested in scheduling a meeting with Reunion’s management team, or for more information on the conference, please contact KCSA Strategic Communications at Reunion@kcsa.com.

About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)

Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.

Learn more at https://investors.reunionneuro.com, and https://www.reunionneuro.com.

Follow us on Twitter and Instagram: @reunionneuro.

To be added to the Reunion Neuroscience email list, please email Reunion@kcsa.com with “REUN” in the subject line.

Cautionary Note Regarding Forward-Looking Information 

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.

Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

CONTACTS:

Reunion Neuroscience:Greg MayesPresident & CEO(215) 696-9659gmayes@reunionneuro.com

Media contacts:Caitlin KasunichKCSA Strategic Communications(212) 896-1241reunion@kcsa.com

Investor contacts:Phil Carlson / Sophia BashfordKCSA Strategic Communications(646) 573-0776 / (929) 246-7307reunion@kcsa.com

SOURCE Reunion Neuroscience Inc.